Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

And here’s another reason for the Indians to rejoice. Among the top list of influential executives in the world, there’s an Indian. As per a news report by The Economic Times, <keyword id="6358361" type="CITY" weightage="20" keywordseo="Biocon">Biocon</keyword> <keyword id="1535570" type="POSITION" weightage="20" keywordseo="founder-and-managing-director">founder and managing director</keyword> <keyword id="6413985" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar-Shaw</keyword> has been ranked one of the most influential executives in the world in the field of medicine by a top UK-based medical publication. 
 
Mazumdar-Shaw has been ranked number two on The Medicine Maker Power List of 2015, which is an index of the 100 most influential people across the globe in the field of medicine, an annual list which is compiled by UK-based The Medicine Maker. 
 She has appeared on the list along with of <keyword id="225564" type="PERSON" weightage="20" keywordseo="Anthony-Fauci">Anthony Fauci</keyword>, who is the <keyword id="303" type="POSITION" weightage="20" keywordseo="Director">director</keyword> of the <keyword id="381130" type="ORGANIZATION" weightage="20" keywordseo="National-Institute-of-Allergy">National Institute of Allergy</keyword> and Infectious Diseases, <keyword id="6355055" type="COUNTRY" weightage="20" keywordseo="USA">USA</keyword>, and was ranked number one on the list; <keyword id="78710" type="CITY" weightage="20" keywordseo="GlaxoSmithKline">GlaxoSmithKline</keyword> <keyword id="24211" type="POSITION" weightage="20" keywordseo="chief-executive">chief executive</keyword> Sir Andrew Witty; <keyword id="1872477" type="ORGANIZATION" weightage="20" keywordseo="Calico">Calico</keyword> <keyword id="5645" type="POSITION" weightage="20" keywordseo="CEO">CEO</keyword> <keyword id="835599" type="UNKNOWN" weightage="20" keywordseo="Arthur-D-Levinson">Arthur D Levinson</keyword> and <keyword id="6377429" type="COMPANY" weightage="20" keywordseo="Mylan">Mylan</keyword> CEO <keyword id="1114925" type="PERSON" weightage="20" keywordseo="Heather-Bresch">Heather Bresch</keyword>. 
 
The compilation has been done on the basis of nominations and recommendations from a panel of expert judges. 
 The financial daily further reported, Mazumdar-Shaw is the only India-based <keyword id="94268" type="POSITION" weightage="20" keywordseo="Business-leader">business leader</keyword> who was featured on the list. 
 
 
 (Image: Biocon)

Kiran Mazumdar Shaw is No.2 on
this global list. Know more

<ul><li>Coronavirus vaccines by the <keyword id="150557" type="ORGANIZATION" weightage="20" keywordseo="University-of-Oxford">University of Oxford</keyword> and China are in the most advanced clinical phase and likely the best choice for India according to <keyword id="6358361" type="DEFINITION" weightage="20" keywordseo="biocon">Biocon</keyword> founder <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword>. </li><li>The US <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword> candidates may be more talked about but they will likely be much more expensive. </li><li>“We’re much more comfortable with a jab and a low-cost vaccine, which is what the Oxford and Chinese vaccines are all about,” explained Shaw. </li></ul>Biotechnology companies around the world are going head-to-head to create the <keyword id="9171829" type="UNKNOWN" weightage="20" keywordseo="first-coronavirus-vaccine">first coronavirus vaccine</keyword> as the ongoing pandemic continues to wreak havoc on normal life. Some have a headstart over others. “I think the Oxford vaccine and Chinese vaccine are certainly in the more advanced clinical phase as is the German vaccine. The two US vaccines are, of course, much talked about but we really don’t know whether these RNA vaccines will really work like they’re considered to,” Biocon founder Kiran Mazumdar Shaw told Business Insider as a part of its special series ‘Hangout with BI’. <div type="javascript" title="Custom" contenttype="Video"><cdata><![CDATA[]]></cdata></div> From passive vaccines with RNA and DNA-based approaches to active vaccines, each has its pros and cons. “If you talk about mRNA vaccine, yes, there’s some advantage there but the issue with side-effects is also different,” explained <keyword id="9193157" type="UNKNOWN" weightage="20" keywordseo="ramanan-laxinarayan">Ramanan Laxinarayan</keyword>, the Director of Centre of Disease Dynamics, Economics and Policy (CDDEP). According to him, the risk of vector-based vaccines in India is that there’s a strong possibility that people are already immune to certain adenoviruses because they’ve already been exposed to them. This results in the possibility that the vaccine won’t take. “Every idea out there, every platform has pluses and minuses,” he said. Ordinarily it takes at least five years to develop a viable vaccine. But in these unprecedented times, it’s possible that a solution could present itself in a matter of months. The front runners for a coronavirus vaccine The two US coronavirus vaccine candidates being developed by Pfizer — in collaboration with Fosum and Germany's BioNTech — and Moderna, are based on the genetic material of DNA protein 'spike'. “The jury is out there to see if it’s really going to work and even if it does work, I don’t think that’s a vaccine that India will really benefit from because these are very expensive vaccines,” said Shaw. The ones in the US may not be the best for Indian patients The US coronavirus vaccine candidates need to be stored at -80 degrees Celsius and have to be delivered intravenously. “We’re much more comfortable with a jab and a low-cost vaccine, which is what the Oxford and Chinese vaccines are all about. These are more typical and conventional vaccines,” she explained. China has the lead closely followed by the Indian project underway at Oxford China is currently leading the charge to develop a coronavirus vaccine. <a href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines">Cansino Biological</a> and the Beijing Institute of Biotechnology are using an Ebola-based candidate to develop a adenovirus type 5 vector coronavirus vaccine, currently in Phase-1 and Phase-2 of clinical trials. Another Chinese candidate vaccine is being developed by the Beijing Institute of Biological Products in partnership with <keyword id="522337" type="ORGANIZATION" weightage="20" keywordseo="Sinopharm">Sinopharm</keyword>, which is also conducting Phase 1 and Phase 2 trials simultaneously. Coming in second is the University of Oxford, which is using a non-replicating viral vector approach based on MERS, influenza, TB, chikungunya, Zika and others to develop its coronavirus vaccine. The Serum Institute of India (SII) — the world’s largest vaccine maker — is already manufacturing Oxford’s vaccine even though it doesn’t have approval yet. It's taking the risk of producing up to 400 million doses by the end of the year, if all goes well. Is India working on a coronavirus vaccine? Indian companies, including Biocon, have no intention of being left behind. They are also working on producing a coronavirus vaccine but it's going to take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months</a> before they’re able to get to a clinic, according to Shaw. “The government of India is asking large companies to help the small vaccine biotech companies expedite and advance their programs,” she said. See also: <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months</a> <a href="https://www.businessinsider.in/stock-market/news/moderna-skyrockets-16-to-record-high-after-fda-clears-coronavirus-vaccine-for-phase-2-study/articleshow/75603580.cms">Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study</a>

There are a lot of coronavirus vaccines in the works⁠— but these are the two that Indians should watch out for

New Delhi, April 14 () Extension of the nation-wide lockdown is the right decision as India is witnessing a surge in the number of novel coronavirus infections, Biocon Chairperson Kiran Mazumdar-Shaw said. "The extension of pan-India lockdown till May 3, 2020, is an important and right decision taken by the Prime Minister. India is registering a spike in the number of Covid-19 cases and this is not the time to let our guard down," Mazumdar-Shaw told . Enforcing stricter curbs is critical as any laxity in following lockdown guidelines can worsen the situation, she added. Highlighting the importance of social distancing in curbing the spread of the pandemic, Mazumdar-Shaw said, it "is the best social vaccine for Covid-19 in the current circumstances". Every Indian needs to take up the responsibility of checking the spread of this lethal viral pandemic by adopting all necessary precautions, she added. "The extension of the lockdown will buy India more time to ramp up medical supplies and healthcare infrastructure even as we work to limit the emergence of new Covid-19 transmission hotspots," Mazumdar-Shaw said. Calibrated economic activity can be pursued based on the assessment of the cessation of the spread of the viral infection, but for now extension of the lock down is the most optimal decision, she added. "I believe, the PM's Saptapadi (7-step) guideline encapsulates what we need to do as a country to win this fight against Covid-19 must be followed in letter and spirit, Mazumdar-Shaw said. AKT ANSANS

Extension of lockdown right decision amid spiking Covid-19 cases: Kiran Mazumdar-Shaw

New Delhi, Dec 2 () Biocon Chairperson and Managing Director Kiran Mazumdar Shaw on Monday said India Inc is "neither anti-national nor anti-government", continuing her support for veteran industrialist Rahul Bajaj who stated that India Inc was afraid of criticising the Narendra Modi government.
 Shaw, who had earlier said the government treated India Inc as "pariahs" and doesn't want to hear any criticism of the economy, was responding to Finance Minister Nirmala Sitharman remarks that spreading one's own impression "can hurt national interest" in relation to the statement made by Bajaj on Saturday.
 "Madam we are neither anti national nor anti government. We want you to succeed big time as fastest growing economy n rise to the top of the global league of economies. I am a proud apolitical National n only want the Govt to promote good policies including at State level," Shaw tweeted.
 She was replying to a tweet by Sitharaman who shared a video of The Economic Times' ET Awards event in Mumbai on Saturday where Bajaj, chairman of Bajaj Group, had told Sitharaman, Home Minister Amit Shah and Railway Minister Piyush Goyal on dais that people were afraid of criticising the BJP government's policies and added that no one in the business community would speak about this issue.
 In the tweet, Sitharaman said, "Home Minister @AmitShah answers on how issues raised by Shri. Rahul Bajaj were addressed. Questions/criticisms are heard and answered/addressed. Always a better way to seek an answer than spreading one's own impressions which, on gaining traction, can hurt national interest."
 Supporting Bajaj, Shaw had earlier said, "Hope the govt reaches out to India Inc for working out solutions to revive consumption n growth. So far we are all pariahs n govt does not want to hear any criticism of our economy." RKL MKJ

India Inc neither anti-national nor anti-government: Kiran Mazumdar Shaw

New Delhi, Apr 18 () COVID-19 will reboot the world into virtual reality and after the crisis, work from home models are likely to continue and business travel is likely to be curtailed as virtual meetings have proved to be just as effective, Biocon Executive Chairperson Kiran Mazumdar-Shaw on Saturday said. In a blog post, she said mobile and internet banking have also seen a surge since the viral outbreak. The new world order will now become a virtual reality, she added. "The seismic events unleashed by the COVID-19 pandemic will have a powerful impact on the world we live in, changing it in ways we had never imagined were possible. The economic damage is likely to be unprecedented," Mazumdar-Shaw said. The world economy, worth USD 90 trillion at the start of the current financial year, would have lost USD 5 trillion and moved into recession by the time the next financial year starts, she added. "COVID-19 is the reboot button that will trigger a system-wide overhaul. A year from now, the world we will live in will be very different. It will impact how we live, how we work, and how we use technology," Mazumdar-Shaw said. To quote a recent McKinsey report, "In this unprecedented new reality, we will witness a dramatic restructuring of the economic and social order in which business and society have traditionally operated," she added. This COVID-19 outbreak is a lesson that technology has many faces and being besotted with only one application of computational science is dangerous, Mazumdar-Shaw said. "For humanity to survive, we will need a multi-disciplinary approach to advancing science and technology, combining biotechnology, biomedical technologies, biological sciences, environmental sciences, etc," she added. The novel coronavirus has exposed the huge shortcomings in public healthcare systems, especially in developed countries where they have largely remained static since World War II, she added. Mazumdar-Shaw said the governments will have to bring in policies to address essential healthcare infrastructure, strategic reserves of key supplies, and contingency planning for medical equipment, diagnostics, drugs and vaccines. "COVID-19 will also cast a long shadow on our social and cultural lives," she added. What repercussions these changes will have on the shape of human society only time can tell, Mazumdar-Shaw said. The post-COVID-19 world is unlikely to look like the "normal" we have grown accustomed to in the recent years, she added. "Ultimately, the greatest lesson that COVID-19 can teach humanity is that we are all in this together, that what affects a single person anywhere affects everyone everywhere, that as homo sapiens we need to think and act unitedly rather than worrying about race, ethnicity, nationality, religion, economic status, and such artificial groupings," Mazumdar-Shaw said. AKT HRS

COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw

<ul><li>With the COVID-19 pandemic ravaging several parts of the country, Indians have grown restless and are searching for how to make coronavirus vaccine at home.</li><li>As a result of this, several rumours and fake news are being spread on social media and WhatsApp, misleading people and being potentially harmful.</li><li>Home remedies against coronavirus have also gone viral on social media, misleading people into believing that they are a cure or prevent COVID-19.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a></li></ul>The COVID-19 pandemic is ravaging several parts of India after the nationwide lockdown was partially lifted in June. The fear around the pandemic is increasing and with no proven vaccine readily available, people are now looking to make the COVID-19 vaccine at home. Over the past few days, the searches for how to make COVID-19 vaccine at home have been off the charts. <div type="image" title="how to make coronavirus vaccine at home" msid="76893845" hostid="261"></div> The lack of a cure for COVID-19 has also allowed pranksters and scammers to capitalize on the people’s fears by pedding fake cures and recipes, spreading rumors and fake news on social media, including things like COVID-19 vaccine being ready, or that tuberculosis vaccine can prevent coronavirus, and more. <div type="Article" hostid="261" msid="75591805" title="Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months" mstype="2" mssubtype="0"></div> Why are Indians searching for how to make coronavirus vaccine at home The continuous rise in COVID-19 cases has caused panic amongst people, <a href="https://www.telegraphindia.com/health/dont-panic-its-not-coronavirus/cid/1785580">causing anxiety</a> and a rush to clinics and hospitals. In some cases, these remedies are being touted as a coronavirus vaccine, misleading people into believing that a cure for COVID-19 has been found. The most prominent case is that of Ramdev’s Patanjali, which <a href="https://www.businessinsider.in/business/news/ramdevs-patanjali-claims-to-have-covid-19-medicine-100-recovery-in-7-days/articleshow/76530185.cms">touted that its Coronil and Swasari products were cure for coronavirus</a>, and not just immunity boosters. Soon after, an <a href="https://www.businessinsider.in/india/news/jaipur-fir-lodged-against-ramdev-patanjali-md-over-companys-covid-19-cure/articleshow/76667088.cms">FIR was lodged</a> against the company and it had to <a href="https://www.businessinsider.in/india/news/didnt-promote-covid-19-cure-just-shared-trial-results-patanjali/articleshow/76714300.cms">retract its claims</a>. Home remedies against coronavirus go viral on social media Due to the absence of a coronavirus vaccine and the existing panic amongst people, home remedies against coronavirus have gone viral on social media and WhatsApp. Ayurvedic recipes involving spices like ginger, clove, black pepper, caraway (ajwain) have become popular. However, these home remedies might not be effective against the infection, or even boost immunity, according to a fact-check by IFCN-accredited fact-checker <a href="https://www.altnews.in/home-remedies-by-ayurved-parameshwar-arora-are-they-effective-in-treating-coronavirus/">Alt News</a>. Why does it take so long to develop a vaccine? Vaccine development takes a long time as there are several stages involved in testing and getting the vaccine approved by government regulators. Kiran Mazumdar, founder, Biocon, and Dr. Ramanan Laxminarayan, founder and director of Center for Disease Dynamics, Economics and Policy explain how it takes a long time to make a vaccine and it is not something that you can make at home. <div type="Youtube" id="pjGNff2vjuc" title="Covid Vaccine: Here's why it takes so long to make a vaccine." thumbUrl="https://i.ytimg.com/vi/pjGNff2vjuc/mqdefault.jpg"></div> SEE ALSO: <a href="https://www.businessinsider.in/india/news/hyderabad-nizams-institute-of-medical-science-begins-the-human-clinical-trial-of-covid-19-vaccine/articleshow/76833471.cms">Hyderabad's Nizam's Institute of Medical Science begins the human clinical trial of COVID-19 vaccine</a> <a href="https://www.businessinsider.in/india/news/an-indian-covid-19-vaccine-made-by-bharat-biotech-is-set-to-enter-human-trials/articleshow/76702286.cms">An Indian COVID-19 vaccine made by Bharat Biotech is set to enter human trials</a> <a href="https://www.businessinsider.in/science/health/news/icmr-aims-to-launch-covaxin-covid-19-vaccine-by-august-15/articleshow/76765732.cms">India wants a COVID-19 vaccine by August 15 at the risk of rushing trials and approvals</a>

Here's why Indians are searching on Google for how to make coronavirus vaccines at home

New Delhi, Dec 2 () Finance Minister Nirmala Sitharaman has responded to industrialist Rahul Bajaj's statement that India Inc was afraid of criticising the Narendra Modi government, saying spreading one's own impression "can hurt national interest" - a remark that drew sharp reactions on social media.
At The Economic Times' ET Awards event in Mumbai on Saturday evening, Bajaj, chairman of Bajaj Group, had told Sitharaman, Home Minister Amit Shah and Railway Minister Piyush Goyal on dias that people are afraid of criticising the BJP government's policies and added that no one in the business community would speak about this issue.
Shah had responded to him saying there is "no need to fear about anything. The Narendra Modi government has been criticised continuously in media. But, if you are saying that there is such an environment, we need to work to improve this".
Bajaj found support in Biocon chairperson Kiran Mazumdar Shaw who said the government treated India Inc as "pariahs" and doesn't want to hear any criticism of the economy.
"Hope the govt reaches out to India inc for working out solutions to revive consumption n growth. So far we are all pariahs n govt does not want to hear any criticism of our economy," she tweeted on Sunday evening.
Soon after, Sitharaman tweeted a video of the ET event to say: "Home Minister @AmitShah answers on how issues raised by Shri. Rahul Bajaj were addressed. Questions/criticisms are heard and answered/addressed".
"Always a better way to seek an answer than spreading one's own impressions which, on gaining traction, can hurt national interest," she said.
Her remarks drew varied responses with the opposition Congress seizing on it to criticise the government.
Congress leader and former union minister Kapil Sibal said: "Rahul Bajaj only said: Industry fears to criticise government".
"Does national interest lie in praising you!," he tweeted.
His party spokesperson Salman Anees Soz said that "Only an insecure, incompetent, and intolerant government will stoop so low as to characterize government criticism as against the national interest".
Defending the government, Civil Aviation Minister Hardeep Singh Puri alleged there were fake narratives.
"That Mr Rahul Bajaj could stand up to Sh @AmitShah Ji's face, express himself freely &amp; instigate others to join him clearly indicate that freedom of expression &amp; democratic values are alive &amp; flourishing in India. This is exactly what democracy is all about," he tweeted.
Minister of Railways and Commerce Piyush Goyal referred to Shah's response to Bajaj's remarks to say there is no fear.
"See Home Minister @amitshah respond to Rahul Bajaj's claim that people are afraid to express themselves. "After hearing your question I doubt anybody believes this claim that people are afraid," he tweeted.
A day before the ET event, former Prime Minister Manmohan Singh had stated that many industrialists have told him they lived in fear of harassment by government authorities.
Delivering the valedictory speech at the National Economy Conclave, Singh had on Friday warned: "There is a palpable climate of fear in our society today. Many industrialists tell me they live in fear of harassment by government authorities. Bankers are reluctant to make new loans, for fear of retribution. Entrepreneurs are hesitant to put up fresh projects, for fear of failure attributed to ulterior motives. Technology start-ups that are an important new engine of economic growth and jobs, seem to live under a shadow of constant surveillance and deep suspicion". ANZ
BAL

FM on Bajaj's lack of freedom comment: Spreading one's own impression can hurt national interest

<keyword id="6354512" type="CITY" weightage="80" keywordseo="Infosys">Infosys</keyword> is all set to get a new Chairman in place of <keyword id="396965" type="ORGANIZATION" weightage="80" keywordseo="KV-Kamath">KV Kamath</keyword>, who is taking over the new role as president of BRICS Bank. 
 
On the condition of anonymity, two people familiar with the development said that while Infosys would evaluate external and internal candidates to replace Kamath, it was expected that the conglomerate would name board member R Seshasayee as interim non-executive chairman. 
 
They added that name of the successor would be finalised within two to three weeks. 
 
Economic Times first reported that Infosys had begun hunting for its next chairman and may appoint either Seshasayee, executive vice chairman at Ashok Leyland, or former Microsoft India chairman Ravi Venkatesan as interim chairman to oversee the transition. 
 
Seshasayee, who started his career with Hindustan Lever in 1971 and joined Ashok Leyland in 1976, joined Infosys' board in 2011. He became executive director of Ashok Leyland in 1983 and managing director in 1998. He has also been the chairman of IndusInd Bank since 2007. 
 
"Seshasayee is the most likely candidate to be selected as interim non-executive chairman, given his experience and the fact that he is among the senior-most people on the board," one of the sources told ET. 
 
The person added that it was likely that Infosys would opt for an interim non-executive chairman for now. “Ideally the company would like to have a chairman in place before the AGM (on June 22)," this person said. 
 
Infosys' nominations committee, which identifies and evaluates candidates for various director positions, has the authority to identify and evaluate candidates to replace Kamath. 
 
Besides Kamath, the committee includes board veteran Jeffrey Sean Lehman, Biocon founder Kiran Mazumdar-Shaw and Seshasayee. Technically, a member of the nominations committee can be considered for the position of chairman, the sources said. 
 
Sources told the financial daily that chief executive Vishal Sikka along with Kamath will also explore appointing an external candidate as the next chairman. 
 "Infosys ideally wants the next chairman to have a profile similar to founder NR <keyword id="6355623" type="PERSON" weightage="80" keywordseo="Narayana-Murthy">Narayana Murthy</keyword> or Kamath. That person could come either from within the board or outside Infosys," the second source told ET. 
 
Kamath helped ICICI Bank become a savvy, next-generation lender. He first replaced Murthy as Infosys' chairman in August 2011 and played a vital role in succession planning at the company. 
 
"Infosys needs (a chairman) with experience in institution building. Right now the company is undergoing a serious transition and a lot of changes are taking place under the new CEO. So Infosys needs to pick someone who can be a good sounding board to Sikka," Kavil Ramachandran, executive director, Thomas Schmidheiny Centre for Family Enterprise at the Indian School of Business, told ET. 
 
Ramachandran said it should ideally be someone who Sikka respects and will not be seen a roadblock and also who knows the company well and values the ethos of the founders. 
 
During past five years, Infosys’ chairmanship changed as many as four times. Following two lacklustre years under co-founder SD Shibulal, the company's board brought back Murthy as executive chairman in June 2013 and Kamath moved out of his non-executive role. 
 
After the company appointed Sikka as its first non-founder CEO in August 2014, Murthy stepped down from his executive chairman role and Kamath took over again. 
 
(Image: Indiatimes)

You Searched For "The Economic Times Biocon" and got 8 results

Kiran Mazumdar Shaw is No.2 on this global list. Know more

BI India Bureau

There are a lot of coronavirus vaccines in the works⁠— but these are the two that Indians should watch out for

Prabhjote Gill

Extension of lockdown right decision amid spiking Covid-19 cases: Kiran Mazumdar-Shaw

PTI

India Inc neither anti-national nor anti-government: Kiran Mazumdar Shaw

PTI

COVID-19 will reboot world into virtual reality: Kiran Mazumdar-Shaw

PTI

Here's why Indians are searching on Google for how to make coronavirus vaccines at home

Rounak Jain

FM on Bajaj's lack of freedom comment: Spreading one's own impression can hurt national interest

PTI

Seshasayee likely to be interim chairman while search for Kamath’s successor continues

BI India Bureau

Popular Keywords

Buying Guides